Recent Pfizer Press Releases

  • 6/27/18 8:00 am EDT

    Submission Based on Data from Randomized Phase 2 Trial, Which Showed Glasdegib in Combination with Chemotherapy Nearly Doubled Overall Survival Compared to Chemotherapy Alone

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) accepted the company’s New Drug Application and granted Priority Review designation for glasdegib, an investigational oral smoothened (SMO) inhibitor, being evaluated for the treatment of adult patients with previously untreated acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC), a type of chemotherapy. “Patients with acutemore...
  • 6/25/18 8:00 am EDT
    • Results show a positive trend in the secondary endpoint of overall survival, though not reaching statistical significance
    • IBRANCE is approved worldwide in combination with fulvestrant based on compelling results from the primary endpoint of progression-free survival
    NEW YORK--(BUSINESS WIRE)--Pfizer today announced overall survival (OS) results from the Phase 3 PALOMA-3 trial, which evaluated IBRANCE® (palbociclib) in combination with fulvestrant compared to placebo plus fulvestrant in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer whose disease has progressed after prior endocrine therapy. The results demonstrated a positive trend in the hazard ratiomore...
  • 6/19/18 10:00 am EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, July 31, 2018. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Second Quarter 2018 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at
  • 6/12/18 7:00 am EDT

    Drug Donation Supports the World Health Organization (WHO) Comprehensive Global Health Strategy to Eliminate Trachoma which Disproportionally Affects the Poorest of the Poor

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. announced today it will extend its donation of the antibiotic Zithromax® (azithromycin) to the International Trachoma Initiative through 2025, building on the company’s 20-years of work to help eliminate the world’s leading infectious cause of blindness. Approximately 163 million people are at risk of developing the disease and this recommitment ensures that Pfizer, through the International Trachoma Initiative (ITI), will continuemore...
  • 6/7/18 8:00 am EDT

    U.S. New Drug Application Granted FDA Priority Review

    Submissions Based on Data from EMBRACA, the Largest Phase 3 Trial Performed to Date of a PARP Inhibitor in BRCA-mutated MBC

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug Administration accepted for filing and granted Priority Review designation to the company’s New Drug Application for talazoparib. The submission is based on results from the EMBRACA trial, which evaluated talazoparib versus chemotherapy in patients with germline (inherited) BRCA-mutated (gBRCAm), HER2-negative locally advanced or metastatic breast cancer (MBC). Talazoparib is anmore...
  • 6/6/18 8:00 am EDT

    Approximately 25% of new funding to be dedicated to neuroscience

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced it plans to invest $600 million in biotechnology and other emerging growth companies through Pfizer Ventures, the company’s venture investment vehicle. In addition to increased funding, Pfizer will extend its leadership as a venture capital investor with an expanded team that leverages expertise across venture capital investing, business development, drug discovery and clinical developmentmore...
  • 6/4/18 5:37 pm EDT

    Overall Survival Data from Head-to-Head Phase 3 ARCHER 1050 Trial Comparing Dacomitinib to Gefitinib Presented at ASCO 2018

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced overall survival (OS) data from the ARCHER 1050 trial evaluating dacomitinib as a first-line treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR-activating mutations compared to gefitinib. The trial showed a median OS of 34.1 months for patients receiving dacomitinib (95% CI: 29.5, 37.7), representing a more than seven-month improvement compared to 26.8more...
  • 6/1/18 7:30 am EDT

    TRAZIMERA, a potential biosimilar to Herceptin ® (trastuzumab), is Pfizer’s first therapeutic oncology biosimilar to undergo regulatory review in Europe

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending marketing authorization for TRAZIMERA™, a potential biosimilar to Herceptin® (trastuzumab), for the treatment of HER2 overexpressing breast cancer and HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.1 ”Pfizer ismore...
  • 5/30/18 3:52 pm EDT

    XELJANZ, an Oral Therapy, is the First and Only JAK Inhibitor Approved in the U.S. for This Patient Population

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that the United States (U.S.) Food and Drug Administration (FDA) approved XELJANZ® (tofacitinib) 10 mg twice-daily (BID) for at least eight weeks, followed by XELJANZ 5 mg BID or 10 mg BID, for the treatment of adult patients in the U.S. with moderately to severely active ulcerative colitis (UC).1 “Ulcerative colitis is a chronic inflammatory bowel disease that can significantly impact the livesmore...
  • 5/30/18 7:00 am EDT

    This Second Round of Funding Builds on Initial $6.7 Million Grant Program

    NEW YORK--(BUSINESS WIRE)--The Pfizer Foundation announced today a new $5 million grant commitment to initiatives in low- and middle-income countries that provide family planning access and education for women and men at the same time children are routinely vaccinated. These new grants build on The Pfizer Foundation’s existing grant program by providing a second round of funding to international nongovernmental organizations (INGOs) in five African countries wheremore...